EMEND

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chemotherapy-induced Nausea and Vomiting

Conditions

Chemotherapy-induced Nausea and Vomiting

Trial Timeline

Apr 1, 2007 → Oct 1, 2011

NCT ID

NCT01074255

About EMEND

EMEND is a pre-clinical stage product being developed by Merck for Chemotherapy-induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT01074255. Target conditions include Chemotherapy-induced Nausea and Vomiting.

What happened to similar drugs?

3 of 20 similar drugs in Chemotherapy-induced Nausea and Vomiting were approved

Approved (3) Terminated (4) Active (14)

🔄GranisetronKyowa KirinPhase 3

🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3

🔄Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3

❌Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3

🔄Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3

🔄Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3

❌Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01074255	Pre-clinical	Completed	Apr 1, 2007	Oct 1, 2011	Chemotherapy-induced Nausea and Vomiting

Competing Products

20 competing products in Chemotherapy-induced Nausea and Vomiting

See all competitors

Product	Company	Stage	Hype Score
SON-080	Sonnet BioTherapeutics	Phase 1/2	18
Granisetron	Kyowa Kirin	Phase 3	40
ONO-7746	Ono Pharmaceutical	Phase 1	21
ONO-2910 + Placebo	Ono Pharmaceutical	Phase 2	35
PROCRIT 40,000 IU QW + Placebo	Johnson & Johnson	Phase 2	27
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	47
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 2	42
Hetrombopag + Hetrombopag plus Placebo + Placebo	Jiangsu Hengrui Medicine	Phase 3	44
Hetrombopag + Matching placebo	Jiangsu Hengrui Medicine	Phase 3	32
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	40
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy	Merck	Phase 3	40
Fosaprepitant	Merck	Phase 2	27
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist	Merck	Phase 3	32
Fosaprepitant + Dexamethasone + 5HT3	Merck	Phase 2	35
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone	Merck	Phase 3	40
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)	Merck	Phase 3	40
Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone	Merck	Approved	43
ondansetron clinical trial formulation + ondansetron marketed formulation	Merck	Phase 1	29
Aprepitant + Palonosetron + Dexamethasone	Merck	Phase 2	31
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999	Merck	Phase 1	29